RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38

RBC Capital analyst Lisa Walter has maintained an Outperform rating on Viridian Therapeutics (NASDAQ: VRDN) and raised the price target from $36 to $38. This adjustment reflects a positive outlook for the company's performance in the market.